bioRxiv Science⌕ Search

Biology subjects

Teixeira, D. C.

Publications and source records attributed to Teixeira, D. C..

5 recordsLinked to original sources

CORONAVIRUS INFECTION ACCELERATES EXPERIMENTAL OSTEOPOROSIS THROUGH THE ACTIVATION OF OSTEOCLASTS

Coronavirus infection is increasingly associated with systemic inflammation and extrapulmonary sequelae, including bone loss. However, the impact of coronavirus infection on hosts with pre-existing osteoporosis remains poorly understood. Here, we investigated the effects of infection with the murine coronavirus MHV-A59 on bone remodeling in a mouse model of ovariectomy-induced osteoporosis. Female C57BL/6 mice underwent ovariectomy (OVX) or sham surgery and, after establishment of the osteoporotic phenotype (14 days post-surgery), were intranasally infected with MHV-A59. Clinical, inflammatory, and femur parameters were evaluated throughout acute and chronic phases of infection using histopathological, micro-computed tomography and biochemical analyses. In vitro infection assays with bone-marrow derived macrophages (BMDM) and BMDM-differentiated osteoclasts from Sham and OVX mice were also performed. MHV-A59 induced comparable lung inflammation in Sham and OVX mice. In contrast, infection accelerated bone resorption in OVX mice during the acute phase (5 dpi), whereas in non-osteoporotic animals, infection induced significant bone loss at later stages (60 dpi). These alterations were associated with increased osteoclast differentiation and activity and with elevated levels of osteometabolic and inflammatory mediators, including RANKL, CCL2, CCL3, CCL5, and TGF-{beta}1. In vitro, MHV-A59 infection enhanced the expression of osteoclast-associated markers, including Rank, Traf6, Nfac1, and cathepsin K, and inflammatory mediators by BMDM and osteoclasts. Importantly, these responses were significantly more pronounced in cells derived from OVX mice. Collectively, our findings demonstrate that coronavirus infection promotes bone resorption and accelerates early bone loss in the context of estrogen deficiency, highlighting enhanced osteoclast activity as a potential mechanism underlying this infection-induced phenotype.

cell biology↗

Broad-Spectrum Antiviral Efficacy of 7-Deaza-7-Fluoro-2'-C-Methyladenosine Against Multiple Coronaviruses In Vitro and In Vivo

The Coronaviridae family has been implicated in several major epidemics over the past two decades, including those caused by SARS-CoV, MERS-CoV, and, most recently, SARS-CoV-2. The COVID-19 pandemic, driven by SARS-CoV-2, has led to over seven million deaths worldwide and has been associated with prolonged symptoms, chronic sequelae, and substantial socioeconomic disruptions. The limited availability of effective antiviral treatments, coupled with the ability of coronaviruses to mutate and evade immune defenses, underscores the urgent need for innovative antiviral agents. This study explores the efficacy of the nucleoside analogue DFMA as a potential antiviral agent against multiple Coronaviridae family members, including SARS-CoV-2 and two strains of murine hepatitis viruses (MHV-3 and MHV-A59). In vitro analyses demonstrated that DFMA effectively reduced the viral load in the supernatant of infected cells and enhanced cell viability for both MHV-3 and MHV-A59. Against SARS-CoV-2, DFMA showed a significant reduction in viral load, with a calculated Selectivity Index (SI) of 6.2. In vivo investigations further confirmed the antiviral potential of DFMA. In three distinct murine models--a severe COVID-19 model using MHV-3, a mild COVID-19 model employing MHV-A59, and a transgenic K18-hACE2 mouse model infected with SARS-CoV-2--DFMA administration significantly reduced viral loads in the lungs of infected mice. Additionally, DFMA mitigated inflammatory responses in all models by lowering levels of key inflammatory mediators, such as CXCL1, CCL2, and IL-6. These findings suggest that DFMA possesses broad-spectrum antiviral activity against coronaviruses and may serve as a promising therapeutic candidate for current and future coronavirus outbreaks. Further research is warranted to elucidate its mechanism of action and evaluate its efficacy in clinical settings. ImportanceCoronaviruses have caused significant outbreaks over the past two decades. Since 2020, COVID-19 has resulted in millions of deaths and lasting global impacts. The limited availability of effective antivirals and the viruss ability to mutate and evade vaccines and monoclonal antibody therapy emphasize the urgent need for new treatments. This study investigates DFMA, a promising antiviral candidate, targeting SARS-CoV-2 and two related coronaviruses.Our promising results demonstrated significant antiviral activity of DFMA, not only against SARS-CoV-2 but also against other similar coronaviruses, indicating potential future use against COVID-19 and other possible coronavirus-related diseases.

microbiology↗

PI3Kγ pathway contributes to neuroinflammation and neuronal death induced by Zika virus infection

Zika virus (ZIKV) is an emerging arbovirus belonging to the Flaviviridae family and Orthoflavivirus genus, with a pronounced tropism for the central nervous system (CNS), where it induces neuroinflammation and neuronal death. ZIKV is known to exploit host cellular mechanisms, including the activation of survival pathways such as the PI3K/AKT signaling cascade, to evade apoptosis and enhance its replication. The phosphatidylinositol 3-kinase {gamma} (PI3K{gamma}) pathway regulates critical cellular processes, including differentiation, recruitment, and survival, and is abundantly expressed in both brain tissue and leukocytes. This study aimed to investigate the role of the PI3K{gamma} pathway during ZIKV infection. Primary neuronal cultures from PI3K{gamma}-deficient mice (PI3K{gamma}kd/kd) and human neuroblastoma SH-SY5Y cells treated with the PI3K{gamma} inhibitor AS605240 were infected with ZIKV to assess the impact of PI3K{gamma} signaling on viral replication and neuronal survival. Additionally, interferon /{beta} receptor knockout (A129) mice were treated with AS605240 either before or after ZIKV infection to evaluate the pathways role in neuroinflammation. In vitro, both genetic ablation and pharmacological inhibition of PI3K{gamma} suppressed ZIKV replication and prevented neuronal death. In vivo, mice treated with the PI3K{gamma} inhibitor exhibited enhanced protection against ZIKV infection, characterized by reduced viral load, and diminished brain and optic nerve damage. This neuroprotective effect correlated with altered astrocyte and microglia activation, marked by reduced TNF production in microglia. Furthermore, inhibition of PI3K{gamma} curtailed the recruitment and activation of CD8+ T cells and decreased the production of pro-inflammatory mediators, including IFN-{gamma} and IL-17, in the brains of ZIKV-infected mice. These findings suggest that PI3K{gamma} activation facilitates ZIKV infection and exacerbates neuroinflammation. Pharmacological inhibition of the PI3K{gamma} pathway may offer therapeutic benefits by limiting viral replication and alleviating neuroinflammatory responses during ZIKV infection.

immunology↗

Neuropsychiatric sequelae in an experimental model of post-COVID syndrome in mice

The global impact of the COVID-19 pandemic has been unprecedented, and presently, the world is facing a new challenge known as Post-COVID syndrome (PCS). Current estimates suggest that more than 65 million people are grappling with PCS, encompassing several manifestations, including pulmonary, musculoskeletal, metabolic, and neuropsychiatric sequelae (cognitive and behavioral). The mechanisms underlying PCS remain unclear. The present study aimed to: (i) comprehensively characterize the acute effects of pulmonary inoculation of the betacoronavirus MHV-A59 in immunocompetent mice at clinical, cellular, and molecular levels; (ii) examine potential acute and long-term pulmonary, musculoskeletal, and neuropsychiatric sequelae induced by the betacoronavirus MHV-A59; and to (iii) assess sex-specific differences. Male and female C57Bl/6 mice were initially inoculated with varying viral titers (3x103 to 3x105 PFU/30 L) of the betacoronavirus MHV-A59 via the intranasal route to define the highest inoculum capable of inducing disease without causing mortality. Further experiments were conducted with the 3x104 PFU inoculum. Mice exhibited an altered neutrophil/lymphocyte ratio in the blood in the 2nd and 5th day post-infection (dpi). Marked lung lesions were characterized by hyperplasia of the alveolar walls, infiltration of polymorphonuclear leukocytes (PMN) and mononuclear leukocytes, hemorrhage, increased concentrations of CCL2, CCL3, CCL5, and CXCL1 chemokines, as well as high viral titers until the 5th dpi. While these lung inflammatory signs resolved, other manifestations were observed up to the 60 dpi, including mild brain lesions with gliosis and hyperemic blood vessels, neuromuscular dysfunctions, anhedonic-like behavior, deficits in spatial working memory, and short-term aversive memory. These musculoskeletal and neuropsychiatric complications were exclusive to female mice and were prevented after ovariectomy. In summary, our study describes for the first time a novel sex-dependent model of PCS focused on neuropsychiatric and musculoskeletal disorders. This model provides a unique platform for future investigations regarding the effects of acute therapeutic interventions on the long-term sequelae unleashed by betacoronavirus infection.

neuroscience↗

A suitable murine model for studying respiratory coronavirus infection and therapeutic countermeasures in BSL-2 laboratories

Several animal models are being used to explore important features of COVID-19, nevertheless none of them recapitulates all aspects of the disease in humans. The continuous refinement and development of other options of in vivo models are opportune, especially ones that are carried out at BSL-2 (Biosafety Level 2) laboratories. In this study, we investigated the suitability of the intranasal infection with the murine betacoronavirus MHV-3 to recapitulate multiple aspects of the pathogenesis of COVID-19 in C57BL/6J mice. We demonstrate that MHV-3 replicated in lungs 1 day after inoculation and triggered respiratory inflammation and dysfunction. This MHV-model of infection was further applied to highlight the critical role of TNF in cytokine-mediated coronavirus pathogenesis. Blocking TNF signaling by pharmacological and genetic strategies greatly increased the survival time and reduces lung injury of MHV-3-infected mice. In vitro studies showed that TNF blockage decreased SARS-CoV-2 replication in human epithelial lung cells and resulted in the lower release of IL-6 and IL-8 cytokines beyond TNF itself. Taken together, our results demonstrate that this model of MHV infection in mice is a useful BSL-2 screening platform for evaluating pathogenesis for human coronaviruses infections, such as COVID-19.

microbiology↗